{"filing":{"accession_number":"0000917520-26-000073","cik":"0000917520","ticker":"IART","company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","form":"8-K","filing_date":"2026-10-21","report_date":"2026-10-21","primary_document":"iart-20261021.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/917520/000091752026000073/iart-20261021.htm"},"events":[{"id":36560,"run_id":33708,"accession_number":"0000917520-26-000073","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release for Q3 2026 (quarter ended September 30, 2026). The Item 2.02 disclosure explicitly states that \"Integra LifeSciences Holdings Corporation (the 'Company') issued a press release announcing financial results for the quarter ended September 30, 2026,\" with the press release attached as Exhibit 99.1. The release reports GAAP and adjusted financial metrics including revenues ($411.2M), earnings per diluted share ($0.19 GAAP, $0.59 adjusted), and provides full-year 2026 guidance. This is a material disclosure affecting investor assessment of the company's financial performance and outlook.","company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","filing_date":"2026-10-21","form":"8-K","submitted_at":null,"items":[{"id":41015,"accession_number":"0000917520-26-000073","item_number":"2.02","item_title":"RESULTS OF OPERATIONS AND FINANCIAL CONDITION","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q3 2026 (quarter ended September 30, 2026). The Item 2.02 disclosure explicitly states that \"Integra LifeSciences Holdings Corporation (the 'Company') issued a press release announcing financial results for the quarter ended September 30, 2026,\" with the press release attached as Exhibit 99.1. The release reports GAAP and adjusted financial metrics including revenues ($411.2M), earnings per diluted share ($0.19 GAAP, $0.59 adjusted), and provides full-year 2026 guidance. This is a material disclosure affecting investor assessment of the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T10:16:45.884531+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41015,"accession_number":"0000917520-26-000073","item_number":"2.02","item_title":"RESULTS OF OPERATIONS AND FINANCIAL CONDITION","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q3 2026 (quarter ended September 30, 2026). The Item 2.02 disclosure explicitly states that \"Integra LifeSciences Holdings Corporation (the 'Company') issued a press release announcing financial results for the quarter ended September 30, 2026,\" with the press release attached as Exhibit 99.1. The release reports GAAP and adjusted financial metrics including revenues ($411.2M), earnings per diluted share ($0.19 GAAP, $0.59 adjusted), and provides full-year 2026 guidance. This is a material disclosure affecting investor assessment of the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T10:16:45.884531+00:00","company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","filing_date":"2026-10-21"}]}